Nifuratel (CAS 4936-47-4) Suppliers and Product Information

Nifuratel is a broad-spectrum antibiotic with antimicrobial, antifungal, and antiprotozoal effects. It is particularly effective against common pathogens in gynecological infections, including gram-positive and gram-negative bacteria, trichomoniasis, mold, chlamydia, and mycoplasma.

Uses include treatment of bacterial vaginosis, trichomonas vaginitis, vulvovaginal candidiasis, vaginal mixed infections, urinary tract infections, and gastrointestinal amoebiasis and trichomoniasis.

Frequently Asked Questions about Nifuratel

Q: What is the mechanism of action of Nifuratel?

A: Nifuratel inhibits the IL-6 induced activation of the STAT3 signaling pathway, inducing apoptosis and reducing the growth of human gastric cancer cells. It can reduce the viability of gastric cancer cells and stimulate apoptosis in a dose-dependent manner. Additionally, it induces the arrest of gastric cancer cells in the G2/M phase of the cell cycle.

Q: What are the potential side effects of Nifuratel?

A: Side effects may include gastrointestinal disturbances, peripheral neuropathy, thrombocytopenic purpura, hemolytic anemia in patients with G6PD deficiency, hypersensitivity reactions, contact dermatitis, hepatotoxicity, blood dyscrasias, and pulmonary reactions.

Q: How is Nifuratel synthesized?

A: Nifuratel is synthesized through a process involving the reaction of 5-nitrofuraldehyde diacetate with N-amino-5-methylthiomethyl-2-oxazolidinone under specific conditions, followed by purification steps using glacial acetic acid and activated carbon.